You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GDC-0032

Showing 1 - 25 of 141
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Worldwide (GDC-0032, Tamoxifen)

Completed
  • Breast Cancer
  • Paris, France
  • +13 more
Oct 11, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Metastatic Breast Cancer, Recurrent Breast Cancer Trial in Boston, Nashville (Taselisib, Trastuzumab emtansine, Pertuzumab)

Active, not recruiting
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Boston, Massachusetts
  • +2 more
Mar 21, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

PIK3CA-Related Overgrowth Trial in France (Taselisib (GDC0032))

Terminated
  • PIK3CA-Related Overgrowth
  • Taselisib (GDC0032)
  • Angers, France
  • +17 more
Nov 7, 2019

Advanced Solid Tumours, Breast Cancer Trial in London, Manchester (Palbociclib + Taselisib / Pictilisib)

Unknown status
  • Advanced Solid Tumours
  • Breast Cancer
  • Palbociclib + Taselisib / Pictilisib
  • London, United Kingdom
  • +1 more
Nov 15, 2019

Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma Trial in Canada, United States (Laboratory

Completed
Has Results
  • Recurrent Squamous Cell Lung Carcinoma
  • Stage IV Squamous Cell Lung Carcinoma
  • Birmingham, Alabama
  • +1110 more
Sep 29, 2020

Healthy Volunteers Trial in Nottingham ([14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule)

Completed
Has Results
  • Healthy Volunteers
  • Nottingham, United Kingdom
    Quotient Sciences
Jan 17, 2023

Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)

Completed
  • Brain and Central Nervous System Tumors
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 13, 2023

Dermatitis, Atopic Trial in Canada, Japan, United States (Spesolimab)

Terminated
Has Results
  • Dermatitis, Atopic
  • Scottsdale, Arizona
  • +9 more
Jun 28, 2022

Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)

Not yet recruiting
  • Breast Cancer
  • Breast Cancer, Early-Onset
  • (no location specified)
Jan 18, 2023

Colorectal Cancer, NSCLC Trial (GDC-1971, Osimertinib, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • (no location specified)
Jul 12, 2023

Brain Metastases, Leptomeningeal Metastasis Trial in United States (GDC-0084, whole brain radiation therapy radiation)

Recruiting
  • Brain Metastases
  • Leptomeningeal Metastasis
  • GDC-0084
  • whole brain radiation therapy radiation
  • Miami, Florida
  • +9 more
Jan 3, 2023

Acute Graft-versus-host Disease Trial in Duarte (GDC-8264)

Recruiting
  • Acute Graft-versus-host Disease
  • Duarte, California
    City of Hope National Medical Center
Jan 12, 2023

Lymphocytic Leukemia, Chronic, DLBCL Trial in Australia, United States (GDC-0853)

Completed
  • Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
  • Stanford, California
  • +9 more
Jun 16, 2022

NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • Busan, Korea, Republic of
    Pusan National University Hospital
Apr 3, 2023

Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough Trial (drug, other,

Not yet recruiting
  • Chronic Refractory Cough (CRC) With Non-atopic Asthma
  • +4 more
  • (no location specified)
Jan 9, 2023

Breast Cancer Trial in Boston (Trastuzumab, GDC-0084)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 2, 2022

NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Duarte, California
  • +68 more
Jan 10, 2023

Breast Cancer Trial in Worldwide (GDC-9545, Palbociclib, LHRH Agonist)

Active, not recruiting
  • Breast Cancer
  • Aurora, Colorado
  • +23 more
Jan 30, 2023

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023

Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, ABT-199)

Active, not recruiting
  • Chronic Lymphocytic Leucemia
  • Cologne, Germany
    German CLL Study Group
Sep 14, 2022

Triple Negative Breast Cancer Trial in Portugal, Spain (Ipatasertib, Capecitabine, Eribulin)

Recruiting
  • Triple Negative Breast Cancer
  • Amadora, Lisboa, Portugal
  • +16 more
Jun 10, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Treating Recurrent Stage IV Squamous Cell Lung Cancer

Active, not recruiting
  • Recurrent Squamous Cell Lung Carcinoma
  • Stage IV Squamous Cell Lung Carcinoma AJCC v7
  • Birmingham, Alabama
  • +1003 more
Nov 29, 2021